Status:
RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension
Lead Sponsor:
University of North Texas Health Science Center
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Ther...
Detailed Description
The endoplasmic reticulum is a multipurpose organelle found in most human cells, including those in the brain and the endothelium of blood vessels. One of the primary functions of the endoplasmic reti...
Eligibility Criteria
Inclusion
- 18 to 80 years of age
- No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
- Systolic blood pressure \<140 mmHg; diastolic blood pressure \<90 mmHg (obtained at the Screening and Familiarization Visit)
- Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)
- Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit)
- Body mass index (BMI) \<35 unless athletic/muscular build; calculation = body weight (kg)/height (m2);
- Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal
Exclusion
- Not meeting the defined age criteria
- Body mass index (BMI) \>35 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
- Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
- Positive pregnancy test
- Females with an erratic/irregular menstrual cycle
- Females who are breastfeeding
- Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon)
- Subjects who weigh less than 80 lbs.
- Use of prescription drugs, non-prescription drugs, dietary supplements or herbal medicines known to alter vascular function unless cleared prior to the study
- Use of beta blockers
- Daily use of bronchodilators
- Use of anti-coagulant therapy
- Implanted medical devices (e.g. cardiac pacemaker)
- Current or past history of hyperthyroidism, or other thyroid hormone-related disease
- Current use of hormone replacement therapy (e.g., estrogen, testosterone)
- HbA1c \>5.6
- Resting systolic blood pressure of \<100 mmHg; \>140mmHg or diastolic blood pressure \>90mmHg
- Abnormal 12-lead ECG or uncontrolled heart rhythm issues causing symptoms, or an unstable blood pressure
- History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy)
- Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)
- History of concussion and or other loss of consciousness within the preceding 30 days
- Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder)
- Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)
- Any prior history of anaphylaxis, not just prior reactions to the materials used in this study
- Severe phobia of needles
- Latex allergy aa) Known allergies or sensitivities to substances used in the study (e.g., Lidocaine HCL, sodium nitroprusside, acetylcholine, phentolamine, L-NAME, TUDCA, or related drugs) bb) Donated blood within the last 60 days cc) History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs dd) History of alcohol or drug abuse which inhibits the subject's ability to complete this study ee) Individuals who have had mastectomies ff) History of methemoglobinemia gg) Current diagnosis of anemia hh) Current Fever (oral temp \>99.5 °F/ 37.5 °C) ii) Current use of PDE3 inhibitors (e.g., Viagra) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), or unwillingness to withhold medication for 2 weeks prior to laboratory testing jj) Current diagnosis of cancer kk) Cardiac surgery or cardiac events (e.g., coronary artery bypass graft surgery, myocardial infarction, heart failure) ll) Diagnosis of neurological disease or cognitive dysfunction
Key Trial Info
Start Date :
August 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06025630
Start Date
August 15 2023
End Date
December 31 2028
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76107